Algiax Pharmaceuticals GmbH
algiax.com
Actively hiring
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
News – Events About Us Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
News
Algiax Pharmaceuticals: Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain
Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported
Read more
Report
Algiax Pharma announces positive data from phase 2a trial evaluating AP-325 in patients with neuropathic pain
Algiax Pharma announces positive data from phase 2a trial evaluating AP-325 in patients with neuropathic pain
Read more
Report
Algiax Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of AP-325 in Chronic Neuropathic Pain
Read more
Report
Algiax Pharmaceuticals Expands Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain with 12 New Clinical Sites in Belgium and France
Read more
Report
Report